Editoria e Media
Visiongain publishes Asthma & COPD Therapies Market 2020-2030 report
Where is the COPD and asthma therapeutics market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
Our 310+ page report provides 370+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing COPD and Asthma Therapeutics Market. See how to exploit the opportunities.
• In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
This Visiongain report includes data analysis and invaluable insight into how will affect your industry. Access this report today.
To access the data contained in this document please email contactus@visiongain.com
– Anticholinergics: Spiriva, Atrovent, Eklira, Others
– SABA: Ventolin, ProAir, Proventil, Xoponex, Others
– LABA: Foradil, Arcapta/Onbrez, Brovana, Serevent, Others
– Corticosteroids: Pulmicort, Flixotide, QVAR, Asmanex, Others
– Anti-Leukotrienes: Singulair, Others
– Monoclonal Antibodies: Xolair, Cinqair, Nucala, Benralizumab, Lebrikizumab, Dupilumab
– Others
– Advair
– Symbicort
– Combivent
– Dulera
– Relvar/Breo
– Others
• Oral
• Inhaled
• Others
• Retail pharmacies
• Hospital pharmacies
• Others
• North America
– U.S.
– Canada
• Europe
– Germany
– France
– UK
– Italy
– Spain
– Rest of Europe
• Asia Pacific
– China
– Japan
– India
– Rest of APAC
• Rest of the World
The report also includes profiles and for some of the leading companies in the COPD and asthma therapeutics Market, with a focus on this segment of these companies' operations.
There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., Germany , UK and Japan , China in particular, will continue to achieve high revenue growth to 2030.
Overall world revenue for COPD and Asthma Therapeutics Market will surpass US$ xx million in 2020, our work calculates. We predict strong revenue growth through to 2030.
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
In summary, our 310+ page report provides you with the following knowledge:
• Revenue forecasts to 2030 for COPD and Asthma Therapeutics Market, with forecasts for Treatment, Route of Administration, and Distribution Channel, each forecasted at a global and regional level– discover the industry's prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2030 for 4 regional and 10 key national markets – See forecasts for the COPD and Asthma Therapeutics market in North America , Europe , Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada , Germany , France , UK, Italy , Spain , China , India , and Japan .
• Prospects for established firms and those seeking to enter the market– including company profiles for 12 of the major companies involved in the COPD and Asthma Therapeutics Market. Some of the company's profiles in this report include AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Teva, Merck, F. Hoffmann-La Roche AG.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
AstraZeneca
Boehringer Ingelheim
Cipla
F.Hoffmann-La Roche AG
GlaxoSmithKline
Merck
Mundipharma
Novartis
Pulmatrix
Respiratorius AB
Teva
TFF PHARMACEUTICALS, INC
American Lung Association
Asthma & Bronchitis Association of India
Asthma and Allergy Foundation of America
Asthma Society of India
Asthma.com
European Federation of Allergy and Airway Diseases
European Federation of Allergy and Airways Diseases
European Lung Foundation
European Respiratory Society
European Respiratory Society
National Heart, Lung, and Blood Institute
The American Academy of Allergy, Asthma & Immunology
The Asthma UK and British Lung Foundation Partnership
World Health Organization
Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg